The gonadorelin acetate market was valued at USD 401.7 Mn by 2019. Rising prevalence of amenorrhea and infertility experienced in the female population worldwide primarily drives the gonadorelin acetate market growth. Additionally, the clinical application of gonadorelin acetate in veterinary use further bolsters its market growth.

Gonadorelin is basically a synonym for gonadotropin-releasing hormone, it is a synthetic decapeptide that is vital in releasing the follicle-stimulating hormone (FSH) and luteinizing hormone from the anterior pituitary gland.

The major segments related to the gonadorelin acetate market are: 

By Clinical Application (2017–2027; US$ Mn)

Infertility

Amenorrhea

Veterinary Use

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global gonadorelin acetate market
• The overall segmentation of the gonadorelin acetate market, by clinical application, distribution channel and geography is minutely studied. Amenorrhea and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Significant increase in the number of women population suffering with gonadotropin-releasing hormone deficiency worldwide
• Gonadorelin acetate is recommended for veterinary use only in some countries for estrous synchrony in lactating dairy cows

Report gist?

• The study of the global gonadorelin acetate market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of gonadorelin acetate on account of a significant increase in the number of women population suffering with gonadotropin-releasing hormone deficiency worldwide
• The report will benefit researchers engaged in the development of gonadorelin acetate for veterinary use throughout the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to gonadorelin acetate market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Amenorrhea is currently spearheading the clinical application segment for the gonadorelin acetate market. It is defined as the absence of a menstrual period in the women during her reproductive age. The various factors associated with the occurrence of menarche in the young female population are deficiency of gonadotropin-releasing hormone, physical or emotional stress, etc. Infertility is observed at a higher rate in the developed regions worldwide on account of early age obesity, sedentary lifestyle, unhealthy diet, etc. which diminishes the release of gonadotropin-releasing hormone which is essential for both the growth and release of mature eggs from the ovaries. Veterinary use is expected to register rampant market growth in many countries across the globe, gonadorelin acetate is being widely used for veterinary use for its therapeutic efficacy in the treatment of cystic ovaries in dairy cattle. 

Hospital pharmacy is leading the distribution channel segment for the gonadorelin acetate market. The drug is associated with severe adverse effects and it is mandatory that is must be compounded by the hospital pharmacist in accordance to the doctor’s prescription. Retail pharmacy is gaining huge demand worldwide on account of the flourishing generic drugs market and availability of gonadorelin acetate for veterinary use at affordable prices. 

North America is currently dominating the geography segment for the gonadorelin acetate market. The rising prevalence of amenorrhea in the women population primarily drives the gonadorelin acetate market growth in the region. According to the latest research citings presented by the National Institute of Health (NIH), approximately 1% of the women population in the United States suffer with amenorrhea. Further research studies suggest that childhood obesity is the major causative factor for the occurrence of early menarche. Recently USFDA has given approval to Fertagyl® for its clinical application in estrous synchrony in lactating dairy cows. Europe is placed in the 2nd position in the geography segment for gonadorelin acetate market. The rising prevalence of infertility in the European Union region propels the gonadorelin acetate market growth. According to the statistics provided by the European Commission report, the number of children per woman is 1.59 in the European Union region. Asia Pacific is anticipated to be the fastest-growing regional segment for the gonadorelin acetate market. Rising prevalence of gonadotropin-releasing hormone deficiency in women population due to lack of nutritious diet and flourishing generic drugs market together drive the gonadorelin acetate market growth in the Asia Pacific.